Dexmedetomidine and Outcomes of Cardiac Surgery (DOCS) (DOCS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02237495|
Recruitment Status : Completed
First Posted : September 11, 2014
Last Update Posted : July 3, 2018
|Condition or disease||Intervention/treatment||Phase|
|Heart Valve Diseases Coronary Artery Disease||Drug: dexmedetomidine Drug: placebo||Phase 2 Phase 3|
There are about 694,000 open-heart surgeries performed in US each year. The major complication rates for valve plus coronary artery bypass graft (CABG) procedure are as high as 30.1% in Society of Thoracic Surgeons (STS) reports. Postoperative delirium, infection, acute renal failure (ARF) and major adverse cardiocerebral events (MACE) which include permanent or transient stroke, coma, perioperative myocardial infarction (MI), heart block and cardiac arrest represent the major postoperative complications. These complications translate into increased mortality and prolonged hospital stays with estimated costs exceeding $20 billion annually.6 The etiologies of these adverse events are multifactorial, but one major contributing factor is the surgical stress responses that result in increasing plasma levels of epinephrine and norepinephrine, with consequent myocardial oxygen supply demand imbalance and myocardial ischemia. More than 50% of all perioperative complications are related to adverse cardiovascular events.
The alpha-2 receptor agonists (clonidine, dexmedetomidine) currently used in clinical practice have many desirable effects that may provide myocardial protection including analgesia, anxiolysis, inhibition of central sympathetic outflow and reduction of systemic norepinephrine release that improve hemodynamic stability and positively affect myocardial oxygen supply and demand. The most widely studied alpha-2 agonist is clonidine, a long-acting partial agonist with an alpha-2 to alpha-1 selectivity ratio of 39:1. However, dexmedetomidine is a highly selective, shorter-acting intravenous alpha-2 agonist with an alpha-2 to alpha-1 selectivity ratio of 1300:1.
Multiple studies have reported that dexmedetomidine has a protective effect on specific organs including heart, brain, kidney and lungs. In addition, dexmedetomidine has been shown to have anti-inflammatory properties decreasing mortality and attenuating plasma cytokine concentrations in laboratory animals exposed to endotoxin in a dose-dependent fashion. The investigators hypothesized that dexmedetomidine may provide myocardial, brain, renal and immune function protection for cardiovascular surgical patients. The specific aim of this study was to investigate whether the perioperative use of dexmedetomidine is associated with improved outcomes and a decreased incidence in postoperative mortality, MACE or other complications in patients undergoing open-heart surgery.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery|
|Actual Study Start Date :||April 9, 2014|
|Actual Primary Completion Date :||March 1, 2017|
|Actual Study Completion Date :||March 2018|
Placebo Comparator: Saline
Normal saline as placebo is continuously infused right after anesthesia induction and lasts for 12 hrs with the same infusion rate as the comparator dexmedetomidine
The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
dexmedetomidine intravenous infusion starts right after anesthesia induction in the operating room and last for 12 hours into ICU with a infusion dose of 0.4 ug/kg/h. To avoid potential cause of bradycardia, no dexmedetomidine bolus is given.
dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
Other Name: Precedex
- In-hospital all cause of mortality and major postoperative complications [ Time Frame: The participants will be tightly observed for the duration of hospital stay, an expected average of 10 days ]Postoperative delirium, infection, acute renal failure (ARF) and major adverse cardiocerebral events (MACE) which includes permanent or transient stroke, coma, perioperative myocardial infarction (MI), heart block and cardiac arrest represent major postoperative complications.
- All cause mortality and major complications [ Time Frame: at 30 days and 1 year after operation ]Infection, renal failure, need for dialysis, and major adverse cardiocerebral events (MACE) which includes permanent or transient stroke, coma, perioperative myocardial infarction (MI), heart block and cardiac arrest represent major complications
- postoperative hospital stay [ Time Frame: the number of days between the operation and discharge, an expected average of 12 days ]Record the time of post operative stay
- ICU-stay [ Time Frame: the number of days the patients stay in the ICU after surgery, an expected average of 3 days ]It is the length of stay in ICU
- Incidence of prolonged ventilation [ Time Frame: the duration of intubation is the time from trachea intubation to extubation, an expected average of 20 hours ]Prolonged ventilation is defined as patients remaining on the ventilator for more than 48 hours
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02237495
|Xi'an, Shaanxi, China, 710032|
|Study Chair:||Hailong Dong, M.D., Ph.D.,||Xijing Hospital|